Department of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Front Horm Res. 2021;54:140-153. doi: 10.1159/000513805. Epub 2021 Mar 9.
Childhood cancer survivors (CCS) are at increased risk of developing thyroid disorders during follow-up. Radiation therapy to a field that includes the thyroid gland and 131I-meta-iodobenzylguanidine (131I-MIBG) treatment are the main risk factors for thyroid sequelae, which include decreased thyroid function, hyperthyroidism, thyroid nodules, and differentiated thyroid cancer, specifically papillary thyroid carcinoma. In addition, treatment with anti-neoplastic drugs or immunotherapy may result in thyroid dysfunction. Central hypothyroidism may be seen in CCS after cranial radiotherapy, after immunotherapy, or secondary to a brain tumor that involves the hypothalamic-pituitary region and will be discussed elsewhere in this series. In this chapter, the prevalence, risk factors, surveillance, and management of primary hypothyroidism, hyperthyroidism, thyroid nodules, and differentiated thyroid carcinoma in CCS are discussed.
儿童癌症幸存者(CCS)在随访期间发生甲状腺疾病的风险增加。放射性治疗包括甲状腺区域和 131I-间碘苄胍(131I-MIBG)治疗是甲状腺后遗症的主要危险因素,包括甲状腺功能减退、甲状腺功能亢进、甲状腺结节和分化型甲状腺癌,特别是甲状腺乳头状癌。此外,抗肿瘤药物或免疫疗法的治疗可能导致甲状腺功能障碍。CCS 在颅放疗后、免疫治疗后或继发于涉及下丘脑-垂体区域的脑肿瘤后可能出现中枢性甲状腺功能减退,将在本系列的其他地方讨论。在这一章中,讨论了 CCS 中原发性甲状腺功能减退、甲状腺功能亢进、甲状腺结节和分化型甲状腺癌的患病率、危险因素、监测和管理。